License enhances NeoStem's Presence in Anti-Aging Arena
NEW YORK, Feb. 23 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Alternext US: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today it has signed a license agreement to obtain the exclusive worldwide rights to innovative stem cell technology and applications for cosmetic facial and body procedures and skin rejuvenation.
The licensed technology, which includes an issued as well as pending patent application, was developed by Vincent C. Giampapa, M.D., F.A.C.S., a Board-certified plastic reconstructive surgeon and Assistant Clinical Professor of Plastic and Reconstructive Surgery at the
"We are extremely pleased to sign this agreement with Dr. Giampapa," said Robin Smith, MD, CEO of NeoStem, "Acquisition of the exclusive worldwide rights to these innovative stem cell skin rejuvenation procedures enhances NeoStem's leadership in the anti-aging and regenerative medicine arena. This has long been one of our core pursuits. Our earliest stem cell collection center is focused on treatments for physical aging. Recently, we agreed to acquire through a series of contractual arrangements, control over Shandong New Medicine Research Institute of Integrated Traditional and Western Medicine Limited Liability Company, a China limited liability company. Shandong is a leader in integrated traditional and western medicine in the People's Republic of China, and provides a multitude of treatments including cell regenerative therapies."
In January 2009, Dr. Giampapa presented and demonstrated some of his
|SOURCE Neostem, Inc.|
Copyright©2009 PR Newswire.
All rights reserved